Compare Stocks: RNTX, ANIK, ELDN, and SRZN

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANIK Anika Therapeutics	$21.78	$17.05	$8.37 ▼ $22.88	$291.42M	0.2	136,652 shs	340,387 shs
ELDN Eledon Pharmaceuticals	$3.45	$3.73	$1.35 ▼ $4.60	$280.35M	0.98	954,076 shs	743,905 shs
RNTX Rein Therapeutics	$0.82	$0.87	$0.69 ▼ $2.18	$70.57M	1.39	480,618 shs	579,503 shs
SRZN Surrozen	$23.99	$23.11	$10.73 ▼ $35.00	$278.52M	0.52	281,370 shs	149,722 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANIK Anika Therapeutics	0.00%	+1.30%	+45.69%	+46.37%	+125.70%
ELDN Eledon Pharmaceuticals	0.00%	-2.54%	-3.63%	-11.31%	+32.69%
RNTX Rein Therapeutics	0.00%	+1.49%	+3.37%	-20.58%	-35.59%
SRZN Surrozen	0.00%	+0.13%	+21.59%	-9.03%	+113.81%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANIK Anika Therapeutics	$21.78	$17.05	$8.37 ▼ $22.88	$291.42M	0.2	136,652 shs	340,387 shs
ELDN Eledon Pharmaceuticals	$3.45	$3.73	$1.35 ▼ $4.60	$280.35M	0.98	954,076 shs	743,905 shs
RNTX Rein Therapeutics	$0.82	$0.87	$0.69 ▼ $2.18	$70.57M	1.39	480,618 shs	579,503 shs
SRZN Surrozen	$23.99	$23.11	$10.73 ▼ $35.00	$278.52M	0.52	281,370 shs	149,722 shs

7 Energy Stocks to Buy and Hold Forever

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANIK Anika Therapeutics	0.00%	+1.30%	+45.69%	+46.37%	+125.70%
ELDN Eledon Pharmaceuticals	0.00%	-2.54%	-3.63%	-11.31%	+32.69%
RNTX Rein Therapeutics	0.00%	+1.49%	+3.37%	-20.58%	-35.59%
SRZN Surrozen	0.00%	+0.13%	+21.59%	-9.03%	+113.81%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANIK Anika Therapeutics	2.75	Moderate Buy	$21.00	-3.58% Downside
ELDN Eledon Pharmaceuticals	2.50	Moderate Buy	$9.67	180.19% Upside
RNTX Rein Therapeutics	2.25	Hold	$6.00	633.50% Upside
SRZN Surrozen	2.71	Moderate Buy	$45.00	87.58% Upside

Current Analyst Ratings Breakdown

Latest RNTX, ANIK, ELDN, and SRZN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/21/2026	RNTX Rein Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/20/2026	SRZN Surrozen	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$51.00
8/20/2026	SRZN Surrozen	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$51.00
8/18/2026	RNTX Rein Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/10/2026	SRZN Surrozen	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$44.00
8/5/2026	ANIK Anika Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
8/3/2026	RNTX Rein Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/30/2026	ANIK Anika Therapeutics	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$18.00 ➝ $21.00
7/30/2026	ANIK Anika Therapeutics	Barrington Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$21.00
7/28/2026	SRZN Surrozen	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
7/21/2026	ELDN Eledon Pharmaceuticals	Rodman & Renshaw Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$12.00

(Data available from 8/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANIK Anika Therapeutics	$112.82M	2.58	N/A	N/A	$9.95 per share	2.19
ELDN Eledon Pharmaceuticals	N/A	N/A	N/A	N/A	$1.35 per share	N/A
RNTX Rein Therapeutics	N/A	N/A	$0.06 per share	14.31	($1.07) per share	N/A
SRZN Surrozen	$3.48M	80.04	N/A	N/A	($19.21) per share	-1.25

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANIK Anika Therapeutics	-$10.88M	-$0.27	N/A	75.10	15.56	-3.14%	0.20%	0.15%	11/4/2026 (Estimated)
ELDN Eledon Pharmaceuticals	-$45.62M	-$0.91	N/A	N/A	N/A	N/A	-149.63%	-50.84%	N/A
RNTX Rein Therapeutics	-$49.87M	-$1.72	N/A	N/A	N/A	N/A	N/A	-63.69%	N/A
SRZN Surrozen	-$242.03M	-$40.55	N/A	N/A	N/A	-2,885.33%	N/A	-93.62%	11/6/2026 (Estimated)

Latest RNTX, ANIK, ELDN, and SRZN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q2 2026	RNTX Rein Therapeutics	-$0.27	-$0.10	+$0.17	-$0.10	N/A	N/A
8/13/2026	Q2 2026	ELDN Eledon Pharmaceuticals	-$0.1580	-$0.27	-$0.1120	-$0.27	N/A	N/A
8/6/2026	Q2 2026	SRZN Surrozen	-$1.29	-$0.41	+$0.88	-$0.41	$0.47 million	$5.00 million
7/29/2026	Q2 2026	ANIK Anika Therapeutics	$0.03	$0.42	+$0.39	$0.24	$29.21 million	$32.61 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANIK Anika Therapeutics	N/A	N/A	N/A	N/A	N/A
ELDN Eledon Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
RNTX Rein Therapeutics	N/A	N/A	N/A	N/A	N/A
SRZN Surrozen	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANIK Anika Therapeutics	N/A	4.48	3.19
ELDN Eledon Pharmaceuticals	N/A	7.90	7.90
RNTX Rein Therapeutics	N/A	4.27	4.27
SRZN Surrozen	N/A	12.14	12.14

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANIK Anika Therapeutics	91.53%
ELDN Eledon Pharmaceuticals	56.77%
RNTX Rein Therapeutics	90.89%
SRZN Surrozen	66.57%

Insider Ownership

Company	Insider Ownership
ANIK Anika Therapeutics	12.08%
ELDN Eledon Pharmaceuticals	9.60%
RNTX Rein Therapeutics	1.50%
SRZN Surrozen	31.74%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANIK Anika Therapeutics	300	13.38 million	11.77 million	Optionable
ELDN Eledon Pharmaceuticals	10	81.26 million	73.46 million	Optionable
RNTX Rein Therapeutics	9	86.27 million	84.97 million	N/A
SRZN Surrozen	80	11.61 million	7.93 million	Not Optionable

RNTX, ANIK, ELDN, and SRZN Headlines

Recent News About These Companies

Surrozen, Inc. (NASDAQ:SRZN) Given Consensus Rating of "Moderate Buy" by Brokerages

2 hours ago | marketbeat.com

Surrozen (NASDAQ:SRZN) Research Coverage Started at William Blair

August 23 at 2:00 AM | americanbankingnews.com

William Blair Upgrades Surrozen (NASDAQ:SRZN) to "Strong-Buy"

August 21 at 7:59 AM | marketbeat.com

What is HC Wainwright's Forecast for Surrozen Q3 Earnings?

August 14, 2026 | americanbankingnews.com

What is HC Wainwright's Estimate for Surrozen Q3 Earnings?

August 12, 2026 | marketbeat.com

HC Wainwright Reiterates "Buy" Rating for Surrozen (NASDAQ:SRZN)

August 10, 2026 | marketbeat.com

Surrozen (NASDAQ:SRZN) Issues Quarterly Earnings Results, Beats Expectations By $0.88 EPS

August 6, 2026 | marketbeat.com

Surrozen Reports Second Quarter 2026 Financial Results and Provides Business Update

August 6, 2026 | globenewswire.com

Perceptive Advisors LLC Makes New $6.68 Million Investment in Surrozen, Inc. $SRZN

August 2, 2026 | marketbeat.com

Surrozen, Inc. $SRZN Position Reduced by Stempoint Capital LP

July 30, 2026 | marketbeat.com

Surrozen (NASDAQ:SRZN) Upgraded by Zacks Research to Hold Rating

July 30, 2026 | marketbeat.com

Surrozen (NASDAQ:SRZN) Major Shareholder Sells $6,906,250.00 in Stock

July 29, 2026 | insidertrades.com

Surrozen Inc

July 28, 2026 | edition.cnn.com

Insider Selling: Surrozen (NASDAQ:SRZN) Major Shareholder Sells 325,000 Shares of Stock

July 28, 2026 | marketbeat.com

Surrozen highlights Wnt retina pipeline, SZN-8141 IND timeline at HC Wainwright

July 22, 2026 | msn.com

Surrozen to Present at Upcoming Healthcare Investor Conference

July 15, 2026 | globenewswire.com

Surrozen (SRZN) Stock Forecast & Price Target

June 4, 2026 | investing.com

We're Not Very Worried About Surrozen's (NASDAQ:SRZN) Cash Burn Rate

May 17, 2026 | finance.yahoo.com

Surrozen (SRZN) price target increased by 10.11% to 43.52

May 14, 2026 | msn.com

Surrozen Shareholders Support Board, Auditor and Pay Policies

May 14, 2026 | tipranks.com

Surrozen to Present at Upcoming Healthcare Investor Conference

May 12, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

RNTX, ANIK, ELDN, and SRZN Company Descriptions

Anika Therapeutics NASDAQ:ANIK

$21.78 0.00 (0.00%)

As of 08/21/2026 04:00 PM Eastern

Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management products includes Monovisc and Orthovisc, an injectable HA-based viscosupplement for the pain relief from osteoarthritis conditions; and Cingal, a single-injection OA pain management product to provide both short- and long-term pain relief. The company's joint preservation and restoration product family comprises and orthopedic regenerative solutions, including Hyalofast and Tactoset; sports medicine solutions used to repair and reconstruct damaged ligaments and tendons; and preserving joint solutions, including partial joint replacement, joint resurfacing, and invasive and bone sparing implants, which are designed to treat upper and lower extremity orthopedic conditions. In addition, it offers non-orthopedic products comprising HA-based products for non-orthopedic applications including Hyvisc, a molecular weight injectable HA veterinary product; Hyalobarrier, an anti-adhesion barrier indicated for use after abdominal-pelvic surgeries; and Hyalomatrix used for the treatment of burns and ulcers, as well as products used for the treatment of ears, nose and throat disorders, and ophthalmic products. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.

Eledon Pharmaceuticals NASDAQ:ELDN

$3.45 0.00 (0.00%)

As of 08/21/2026 04:00 PM Eastern

Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.

Rein Therapeutics NASDAQ:RNTX

$0.82 0.00 (0.00%)

As of 08/21/2026 04:00 PM Eastern

Rein Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky on August 6, 2001 and is headquartered in Austin, TX.

Surrozen NASDAQ:SRZN

$23.99 0.00 (0.00%)

As of 08/21/2026 04:00 PM Eastern

Surrozen, Inc., a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043, a hepatocyte-specific R-spondin mimetic bispecific fusion protein, which is in Phase 1b clinical trial for the treatment of severe liver diseases, including alcohol-associated hepatitis. The company develops SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies. Surrozen, Inc. is based in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RNTX, ANIK, ELDN, and SRZN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RNTX, ANIK, ELDN, and SRZN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RNTX, ANIK, ELDN, and SRZN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

RNTX, ANIK, ELDN, and SRZN Company Descriptions

Anika Therapeutics NASDAQ:ANIK

Eledon Pharmaceuticals NASDAQ:ELDN

Rein Therapeutics NASDAQ:RNTX

Surrozen NASDAQ:SRZN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RNTX, ANIK, ELDN, and SRZN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RNTX, ANIK, ELDN, and SRZN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RNTX, ANIK, ELDN, and SRZN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

RNTX, ANIK, ELDN, and SRZN Company Descriptions

Anika Therapeutics NASDAQ:ANIK

Eledon Pharmaceuticals NASDAQ:ELDN

Rein Therapeutics NASDAQ:RNTX

Surrozen NASDAQ:SRZN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools